Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of glioblastoma multiforme by stopping blood flow
to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining thalidomide with irinotecan may kill any tumor cells
remaining after radiation therapy.
PURPOSE: Phase II trial to study the effectiveness of combining thalidomide with irinotecan
in treating patients who have glioblastoma multiforme that has been treated with radiation
therapy.